Showing stock holdings,
see here
for options holdings
Sofinnova Investments, Inc. Q4 2018 Portfolio
Sym
Weight
Trade Impact
Company
Class
Share Change
Activity
Value Change $
Value $
* Price $
Shares
Principal
Filing 2018 Q4 - Restatement compared to 2018 Q3 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Nathalie Auber
Attorney-in-Fact
Menlo Park, California
21 Feb 2019
This Amendment No. 1 is being filed to report the holdings of Nucana plc (f/k/a Nucana Biomed Ltd) in a manner consistent with the Reporting Manager's previous Form 13F filing. For the avoidance of doubt, the Reporting Manager did not dispose of such securities between the filing of the previous Form 13F and this Amendment No. 1.Sofinnova Investments, Inc. is filing this Form 13F on behalf of itself and the general partner entities of the investment funds for which it serves as the investment adviser, Sofinnova Management VII, L.L.C., Sofinnova Management VIII, L.L.C., Sofinnova Management IX, L.L.C., Sofinnova Management X, L.L.C., and Sofinnova BioEquities GP LLC.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.